Anti-Hu CD79b FITC

• Description:

  CD79b (Ig beta, B29) forms disulfide-linked heterodimer with CD79a (Ig alpha, MB1) . They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR) . CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with lambda5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling.

• Certification:

  RUO

• Immunogen:

  Fraction of Ig-associated molecules isolated from Ramos B cells

• Target Antigen:

  CD79b

• Clone:

  CB3-1

• Applications:

  FC (QC tested)

• Format:

  FITC

• Buffer:

  Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

• References & Citations:

  *Nakamura T, Kubagawa H, Cooper MD: Heterogeneity of immunoglobulin-associated molecules on human B cells identified by monoclonal antibodies. Proc Natl Acad Sci U S A. 1992 Sep 15;89 (18) :8522-6., URL: https://www.ncbi.nlm.nih.gov/pubmed/1382292, *Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J, Tan C, Hongo JA, Raab H, Kozak KR, Williams M, McDorman E, Eaton D, Ebens A, Polson AG: In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol Cancer Ther. 2009 Oct;8 (10) :2937-46., URL: https://www.ncbi.nlm.nih.gov/pubmed/19808977, *Garcia Vela J, Delgado I, Benito L, Monteserin M, Garcia Alonso L, Somolinos N, Andreu M, Oña F: CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection. Leukemia. 1999 Oct;13 (10) :1501-5., URL: https://www.ncbi.nlm.nih.gov/pubmed/10516749, *Rassenti LZ, Kipps TJ: Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. Blood. 2000 Apr 15;95 (8) :2725-7., URL: https://www.ncbi.nlm.nih.gov/pubmed/10753858, *Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG: Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009 Sep 24;114 (13) :2721-9., URL: https://www.ncbi.nlm.nih.gov/pubmed/19633198, *Matutes E: New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders. J Clin Pathol. 2002 Mar;55 (3) :180-3., URL: http://www.ncbi.nlm.nih.gov/pubmed/11896067 , *D'Arena G, Cascavilla N, Musto P, Colella Bisogno R, Pistolese G, Carotenuto M: CD79b expression in B-cell chronic lymphocytic leukemia. Haematologica. 2000 May;85 (5) :556-7., URL: http://www.ncbi.nlm.nih.gov/pubmed/10800181

• Storage Conditions:

  Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

• Specificity:

  The mouse monoclonal antibody CB3-1 recognizes an extracellular epitope of CD79b (CD79 beta, Ig beta), an approximately 38 kDa component of B cell receptor (BCR) complex.

• Applications Notes:

  6

• Species:

  Human

• CAS Number:

  9007-83-4

• Isotype:

  Mouse IgG1 kappa